Regeneron Reports Third Quarter 2020 Financial and Operating Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/21/2026
- Wall Street indexes fall, with Iran and earnings season in focus
- Oil settles 1% higher as hopes of renewed US-Iran negotiations offset Houthi threat
- Selloff of U.S. memory stocks creates a compelling entry point: analyst
- Why Moonshot AI's Kimi K3 is actually bullish for memory stocks
- AMC Entertainment soars on record quarterly results
- U.S. to impose 50% tariff on most Canadian goods, including USMCA
- NVIDIA reports 9.3% passive stake in Nebius
- Wall Street indexes fall, with Iran and earnings season in focus
- Cantor Fitzgerald Starts Trulieve Cannabis (TRLV) at Overweight, 'Purpose-Built for a New Cannabis Regulatory Framework'
- Selloff of U.S. memory stocks creates a compelling entry point: analyst
Regeneron (REGN) Tops Q3 EPS by $1.23, Revenues Beat
November 5, 2020 6:50 AM ESTRegeneron (NASDAQ: REGN) reported Q3 EPS of $8.36, $1.23 better than the analyst estimate of $7.13. Revenue for the quarter came in at $2.29 billion versus the consensus estimate of $2.09 billion.
Third quarter 2020 revenues increased 32% to $2.29 billion versus third quarter 2019(4)Third quarter 2020 EYLEA® U.S. net sales increased 11% to $1.32 billion versus third quarter 2019Third quarter 2020 Dupixent® global net sales(2), which are recorded by Sanofi, increased 69% to $1.07 billion versus third quarter 2019Third quarter 2020 GAAP diluted EPS was $7.39... More